Santarus Defends Zegerid Patents In Fed. Circ.

Law360, New York (May 2, 2011, 6:47 PM EDT) -- Santarus Inc. sought to convince the Federal Circuit on Monday that not only were patents it licensed for heartburn drug Zegerid not obvious, as a district court ruled, but that prior art actually teaches away from the claimed invention.

In Santarus’ infringement suit against Par Pharmaceutical Inc. over its efforts to introduce a generic version of Zegerid, a Delaware federal judge ruled in April 2010 that patents held by the University of Missouri and licensed to Santarus for the heartburn drug were invalid due to obviousness....
To view the full article, register now.